Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Huaren Pharmaceutical CoSZSE:300110 55 ROE % is 7.55% as of Mar. 2026, which is 224% above its 10-year median of 2.33. GuruFocus rates SZSE:300110 with a GF Score™ of 55/100 and a GF Value™ of ¥3.13 (Fairly Valued). The stock has 8 warning signs investors should review. Among 934 Drug Manufacturers companies, Huaren Pharmaceutical Co ranks worse than 89.51% on this metric.
Huaren Pharmaceutical Co (SZSE:300110) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Huaren Pharmaceutical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Huaren Pharmaceutical Co ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Huaren Pharmaceutical Co's ROE % distribution charts can be found below:
* The bar in red indicates where Huaren Pharmaceutical Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Huaren Pharmaceutical Co (SZSE:300110) has a ROE % of 7.55% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Huaren Pharmaceutical Co and its competitors. This is 224% above median its historical median of 2.33. According to the industry distribution chart, Huaren Pharmaceutical Co ranks #836 out of 934 companies in the Drug Manufacturers industry, placing it in the top 89.5%.
Is Huaren Pharmaceutical Co's ROE % too high?
Huaren Pharmaceutical Co's current ROE % of 7.55% is 224% above median its 10-year median of 2.33. The Drug Manufacturers industry median ROE % is 6.00. Huaren Pharmaceutical Co's value of 7.55% is 25.8% above this industry median. Based on the distribution chart, Huaren Pharmaceutical Co ranks #836 out of 934 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Huaren Pharmaceutical Co has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Huaren Pharmaceutical Co's ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Huaren Pharmaceutical Co ranks #836 out of 934 companies for ROE %. This places Huaren Pharmaceutical Co in the lower half of its industry. The industry median ROE % is 6.00. Huaren Pharmaceutical Co's value of 7.55% is 25.8% above this benchmark. While the company's 10-year median is 2.33 vs. the industry median of 6.00, Huaren Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Huaren Pharmaceutical Co's current ROE % of 7.55% is 25.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Huaren Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Huaren Pharmaceutical Co's current ROE % is 7.55%, which is 224% above median its own 10-year median of 2.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Huaren Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Huaren Pharmaceutical Co (SZSE:300110) is currently considered Fairly Valued. The stock's GF Value™ is ¥3.13, compared to a current price of ¥2.90 — trading 7.3% below its estimated fair value. The current ROE % is 7.55%, which is 224% above median its 10-year median of 2.33 and 25.8% above the Drug Manufacturers industry median of 6.00. Huaren Pharmaceutical Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Huaren Pharmaceutical Co (SZSE:300110), the current ROE % is 7.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Huaren Pharmaceutical Co (SZSE:300110) Overvalued in 2026?
Based on GuruFocus' analysis, Huaren Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥2.90 is trading 7.3% below its estimated GF Value™ of ¥3.13.
GuruFocus considers Huaren Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SZSE:300110:
ROE %: 7.55% (224% above median its 10-year median of 2.33)
GF Value™: ¥3.13 vs. price of ¥2.90 (7.3% below fair value)
Industry Position: 25.8% above the Drug Manufacturers median (#836 of 934)
No single metric tells the full story. See the SZSE:300110 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Huaren Pharmaceutical Co Ltd is a China-based company engaged in the manufacture, and sale of non-polyvinyl chloride and Non-PVC large capacity preparations. Its categories of products include conventional infusion, therapy infusion, and nutrition infusion. The company distributes its products in domestic market, with Northeast China as its main market.
55GF Score
Get the complete analysis for SZSE:300110
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300110 has been successfully added to your 
